ArticleBMC health services research2025
Prices, availability, and affordability of selected medicines for asthma management in Nigeria: a nationwide study.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent inflation in Nigeria could hinder access to medicines. The aim of the study was to evaluate the prices, availability, and affordability of selected medicines for asthma management in Nigeria.
methodsThis cross-sectional survey (January 2024 - March 2024) was conducted in community pharmacies in the six geopolitical zones of Nigeria. Data for Originator Brand (OB) and Lowest-Priced Generic (LPG) were collected with the Medicine Price Data Collection Form developed by the World Health Organization/Health Action International (WHO/HAI). Twenty-three (23) selected medicines for asthma management were utilised. The Median Price Ratio (MPR) was the ratio of the median local unit price to the international reference unit price (IRP). The IRPs were South African government procurement prices. Availability was reported as the percentage of medicine outlets in which the medicine was found on the day of data collection. Affordability was the number of days of work by the lowest-paid unskilled national government worker to purchase a defined course of treatment for a specific condition.
resultsOf the 300 community pharmacies that were sampled, 214 responses were retrieved (participation rate: 71.3%). The majority of the medicines (n = 18 of 21, 85.7%) were more than two times the international reference unit prices (IRPs). Salbutamol 100 mcg inhaler Originator Brand (OB) was 11.8 times the IRP, while the Lowest-Priced Generic (LPG) was 5.3 times the IRP. The average per cent availability across OBs (11.2%), LPGs (18.8%), and all medicines (15.0%) was less than 50%. The majority of the medicines (n = 36 of 39, 92.3%) cost more than a day's wages. Salmeterol 25 mcg/Fluticasone 125 mcg inhaler would require 31.0 days' wages with OB and 9.5 days' wages with LPG.
conclusionsThe findings reveal high medicine prices, poor availability, and low affordability of asthma medicines. There is a need for targeted subsidies on medicines for the management of asthma, insurance reforms, and local manufacturing incentives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.